Corroborating this idea, the authors show an enhancement of the Ruxolitinib effect in synergy with CDK6 inhibitor Palbociclib, significantly reducing leukocytosis, splenomegaly, and bone marrow fibrosis in Jak2V617F and MPLW515L murine models. Here, CDK6 is linked to primary myelofibrosis.